The Zhitong Finance App learned that Baoji Pharmaceutical-B (02659) rose more than 7% today. As of press release, it had risen 5.02% to HK$8.475, with a turnover of HK$2.158,700.

According to the news, Baoji Pharmaceutical recently had a lot of advantages. According to the company's voluntary announcement on October 20, the new drug clinical trial application (IND) for its self-developed BJ045 injection (subcutaneous injection) has been approved by the State Drug Administration and approved to conduct clinical trials in China. Its approved clinical study marks the company's formation of a collaborative layout of “degrading enzymes+antibodies” in the field of antibody-mediated autoimmune diseases.

Furthermore, according to data disclosed by the Stock Exchange, Chairman Liu Yanjun of the Board of Directors increased his holdings of Baoji Pharmaceutical by a total of 263,300 shares on October 23, 26, and 27, for a total amount of about HK$2.23,300. After the increase in holdings, the latest number of shares held was approximately 264.702 million shares, and the latest shareholding ratio was 17.15%. It further demonstrates confidence in the company's development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.